Guardian Pharmacy (GRDN) | Stock Overview & Key Data
Guardian Pharmacy Performance Comparison
Stock Range
Today's Range
52 Week Range
All-Time High: $41.36 on April 8, 2026
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Financial Highlights
Quarter Income Flow
Dec 31, 2025
Annual Income Flow
2025
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Guardian Pharmacy
GRDN
|
2.40B Mid-cap | 0.05% | 6.82% | 14.98% | 33.77% | 32.54% | 82.99% | 118.25% | 118.25% | 118.25% | 118.25% | 118.25% |
|
HCA Healthcare
HCA
|
106.00B Large-cap | -7.37% | -14.97% | -32.96% | -25.38% | -22.78% | -0.75% | 38.02% | 77.08% | 384.44% | 1,008.79% | 1,116.39% |
|
Tenet Healthcare
THC
|
16.50B Large-cap | -8.96% | -11.07% | -32.13% | -22.00% | -17.35% | 3.88% | 135.08% | 158.85% | 506.43% | 601.28% | 444.47% |
|
Pacs
PACS
|
5.51B Mid-cap | -6.89% | 12.24% | -1.00% | 16.46% | -7.62% | 269.46% | 52.71% | 52.71% | 52.71% | 52.71% | 52.71% |
|
Chemed
CHE
|
5.65B Mid-cap | -2.86% | 0.22% | 0.64% | -0.92% | 0.72% | -25.82% | -21.43% | -14.46% | 221.65% | 544.03% | 685.29% |
|
Option Care Health
OPCH
|
4.48B Mid-cap | -5.13% | -2.89% | -34.20% | -32.15% | -36.32% | -36.14% | -26.93% | 10.60% | 91.12% | -30.99% | 0.14% |
Ownership & Short Interest
Calculate Your Guardian Pharmacy Investment Returns
Long-Term Investment Performance Analysis
Guardian Pharmacy stock price in Sep 2024 was $17.75, A $1,000.00 lump sum investment in Guardian Pharmacy made 1 years ago would be worth approximately $2,205.07 today, representing a strong return of 120.51%. This translates to an annualized return (CAGR) of 59.58%.
1 Year 8 Months Investment Scenario (Sep 2024 - Jun 2026)
Investment Breakdown
Value Comparison
Disclaimer: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing. Past performance does not guarantee future results.
Frequently Asked Questions
- What is GRDN's 52-week high and low?
- In the last 52 weeks, Guardian Pharmacy reached a high of $41.36 (on April 8, 2026) and a low of $19.17 (on June 16, 2025).
- What is the market cap and P/E ratio for GRDN?
- Curious about Guardian Pharmacy's size and valuation? Its market capitalization stands at 2.40B. When it comes to valuation, the P/E ratio (trailing twelve months) is 47.01, and the forward P/E (looking ahead) is 27.08.
- Does GRDN pay dividends? If so, what's the yield?
- As for dividends, Guardian Pharmacy isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Guardian Pharmacy's main competitors or similar companies to consider before investing?
When looking at Guardian Pharmacy, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return HCA Healthcare
HCA106.00B Healthcare Medical Care Facilities -0.75% 38.02% Tenet Healthcare
THC16.50B Healthcare Medical Care Facilities 3.88% 135.08% Pacs
PACS5.51B Healthcare Medical Care Facilities 269.46% 52.71% Chemed
CHE5.65B Healthcare Medical Care Facilities -25.82% -21.43% Option Care Health
OPCH4.48B Healthcare Medical Care Facilities -36.14% -26.93% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Guardian Pharmacy Services Inc.? (e.g., ROE, Debt/Equity)
- To get a sense of Guardian Pharmacy's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 26.62%, the Debt to Equity ratio from the most recent quarter is 20.52, and its Gross Profit Margin stands at 21.50%.
- What is the recent revenue and earnings growth for GRDN?
- Looking at Guardian Pharmacy's growth, its revenue over the trailing twelve months (TTM) was $1B. Compared to the same quarter last year (YoY), quarterly revenue grew by 17.40%, and quarterly earnings saw a YoY growth of 75.20%.
- How much of GRDN stock is held by insiders and institutions?
- Wondering who owns Guardian Pharmacy stock? Company insiders (like executives and directors) hold about 51.48% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 57.70%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.